"Shares of Teva Pharmaceuticals were climbing on the news while Mylan shares were lower. Adamis Pharmaceuticals’ shares were lower. In July, Adamis was granted U.S. approval to sell an EpiPen rival. It will announce the pricing of the product in the second half of the year, according to Reuters."